Advertisement
Oral Presentations Workshop 3. New therapies targeting the airway surface| Volume 15, SUPPLEMENT 1, S6, June 2016

WS03.6 Study of Mul-1867, a drug candidate for inhalation therapy of pulmonary exacerbations in patients with cystic fibrosis against mixed infections caused by clinical isolates of P. aeruginosa, S. aureus and C. albicans in murine lung infection model

Open ArchiveDOI:https://doi.org/10.1016/S1569-1993(16)30077-7
WS03.6 Study of Mul-1867, a drug candidate for inhalation therapy of pulmonary exacerbations in patients with cystic fibrosis against mixed infections caused by clinical isolates of P. aeruginosa, S. aureus and C. albicans in murine lung infection model
Previous ArticleWS03.5 The alginate OligoG CF-5/20 affects quorum sensing pathways in Pseudomonas aeruginosa
Next ArticleWS04.1 Impaired mucus clearance promotes Aspergillus fumigatus-induced type 2 airway inflammation in cystic fibrosis-like lung disease in mice
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S1569-1993(16)30077-7

      Copyright

      © 2016 European Cystic Fibrosis Society. Published by Elsevier Inc.

      User license

      Elsevier user license |
      How you can reuse Information Icon
      Elsevier user license

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Text & data mine
      • Translate the article

      Not Permitted

      • Reuse portions or extracts from the article in other works
      • Redistribute or republish the final article
      • Sell or re-use for commercial purposes

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX